Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD

References

• Griswold DE, Webb EF, Badger AM et al. SB-207499 (Ariflo®), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 287, 705–711 (1998).
   PubMed Web of Science ®Google Scholar
• Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. 157, 351–370 (1998).
   PubMed Web of Science ®Google Scholar
• Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra®), in animal models of airways disease. Am. J. Respir. Crit. Care Med. 169, 227–234 (2004).
   PubMed Web of Science ®Google Scholar
• Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 10, 1361–1379 (2001).
   PubMed Web of Science ®Google Scholar
• Torphy TJ, Barnette MS, Underwood DC et al. Ariflo (SB-207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol. Ther. 12, 131–135 (1999).
   PubMed Web of Science ®Google Scholar
• Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G. Cyclic nucleotide phosphodiesterase Type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155, 4909–4916 (1995).
   PubMed Web of Science ®Google Scholar
• Kambayashi T, Wallin RP, Ljunggren HG. cAMP-elevating agents suppress dendritic cell function. J. Leukoc. Biol. 70, 903–910 (2001).
   PubMedGoogle Scholar
• Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukoc. Biol. 63, 101–107 (1998).
   PubMed Web of Science ®Google Scholar
• Underwood DC, Bochnowicz S, Osborn RR et al. Anti-asthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB-207499 (Ariflo®) in the guinea-pig. J. Pharmacol. Exp. Ther. 287, 988–995 (1998).
   PubMed Web of Science ®Google Scholar
• Profita M, Chiappara G, Mirabella F et al. Effect of cilomilast (Ariflo®) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 58, 573–579 (2003).
   PubMed Web of Science ®Google Scholar
• Kohyama T, Liu X, Zhu YK et al. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastase. Am. J. Respir. Cell Mol. Biol. 27, 487–494 (2002).
   PubMed Web of Science ®Google Scholar
• Kohyama T, Liu X, Wen FQ et al. Cytokines modulate cilomilast response in lung fibroblasts. Clin. Immunol. 111, 297–302 (2004).
   PubMed Web of Science ®Google Scholar
• Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signal. 9, 227–236 (1997).
   PubMed Web of Science ®Google Scholar
• Torphy TJ, Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol. Sci. 21, 157–159 (2000).
   PubMedGoogle Scholar
• Christensen SB, Guider A, Forster CJ et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem. 41, 821–835 (1998).
   PubMed Web of Science ®Google Scholar
• Giembycz MA. 4D or not 4D – the emetogenic basis of PDE4 inhibitors uncovered? Trends Pharmacol. Sci. 23, 548 (2002).
   PubMedGoogle Scholar
• Robichaud A, Stamatiou PB, Jin SL et al. Deletion of phosphodiesterase 4D in mice shortens α(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110, 1045–1052 (2002).
   PubMed Web of Science ®Google Scholar
• Manning CD, Burman M, Christensen SB et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. 128, 1393–1398 (1999).
   PubMed Web of Science ®Google Scholar
• Ariga M, Neitzert B, Nakae S et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173, 7531–7538 (2004).
   PubMed Web of Science ®Google Scholar
• Mudway IS, Kelly FJ. Ozone and the lung: a sensitive issue. Mol. Aspects Med. 21, 1–48 (2000).
   PubMedGoogle Scholar
• Viegi G, Di Pede C. Chronic obstructive lung diseases and occupational exposure. Curr. Opin. Allergy Clin. Immunol. 2, 115–121 (2002).
   PubMedGoogle Scholar
• Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 57, 48–64 (2002).
   PubMedGoogle Scholar
• Vignola AM. PDE4 inhibitors in COPD – a more selective approach to treatment. Respir. Med. 98, 495–503 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med. 167, 813–818 (2003).
   PubMed Web of Science ®Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297, 267–279 (2001).
   PubMed Web of Science ®Google Scholar
• Timmer W, Leclerc V, Birraux G et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol. 42, 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365, 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeire P. The burden of chronic obstructive pulmonary disease. Respir. Med. 96(Suppl. C), S3–S10 (2002).
   Google Scholar
• DeMarsh P, Sucoloski RT-SR, Wells S, Dillon G, Woodnutt G, Collegeville P. Effect of cilomilast, an orally-active, selective PDE4 inhibitor in murine viral/bacterial co-infection model. Am. J. Respir. Crit. Care Med. 163, A381 (2001).
   Google Scholar
• Zussman BD, Benincosa LJ, Webber DM et al. An overview of the pharmacokinetics of cilomilast (Ariflo®), a new, orally-active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J. Clin. Pharmacol. 41, 950–958 (2001).
   PubMed Web of Science ®Google Scholar
• Zussman B, Kelly J, Murdoch RD et al. Ariflo®, a novel and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for drug–drug interactions. Am. J. Respir. Cell Mol. Biol. 161, A492 (2000).
   Google Scholar
• Murdoch RD, Zussman B, Schofield JP, Webber DM. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. J. Clin. Pharmacol. 44, 1046–1053 (2004).
   PubMedGoogle Scholar
• Zussman BD, Davie CC, Kelly J et al. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy 21, 653–660 (2001).
   PubMed Web of Science ®Google Scholar
• Murdoch RD, Cowley H, Upward J et al. The safety and tolerability of Ariflo™ (SB-207499), a novel and and selective phosphodiesterase 4 inhibitor in healthy male volunteers. Am. J. Respir. Crit. Care Med. 157, A409 (1998).
   Google Scholar
• Compton C, Cedar E, Nieman R, Amit O, Langley S, Sapene M. Ariflo™ improves pulmonary function in patients with asthma receiving concomitant corticosteroids. Am. J. Respir. Crit. Care Med. 159, A624 (1999).
   Web of Science ®Google Scholar
• Compton C, Cedar E, Nieman R et al. ArifloTM efficacy in a 12-month study of patients with asthma. Am. J. Respir. Crit. Care Med. 161, A505 (2000).
   Google Scholar
• Gamble E, Grootendorst DC, Brightling CE et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo®) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168, 976–982 (2003).
   PubMed Web of Science ®Google Scholar
• Compton CH, Gubb J, Nieman R et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358, 265–270 (2001).
   PubMed Web of Science ®Google Scholar
• Compton C, Edelson J, Cedar E et al. Cilomilast (Ariflo®) 15 mg b.i.d. safety in a 6 month clinical trial program. Am. J. Respir. Crit. Care Med. 163, A909 (2001).
   Google Scholar
• Edelson J, Compton C, Nieman R et al. Cilomilast (Ariflo®), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: results of a 6 month trial. Am. J. Respir. Crit. Care Med. 163, A277 (2001).
   PubMedGoogle Scholar
• Edelson J, Compton C, Nieman R et al. Cilomilast (Ariflo®) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6 months trial. Am. J. Respir. Crit. Care Med. 163, A771 (2001).
   Google Scholar
• Kelsen S, Rennard SI, Chodosh S, Schryver B, Vleisides C, Zhu J. COPD exacerbation in a 6-month trial of cilomilast (Ariflo®); a potent, selective phosphodiesterase 4 inhibitor. Am. J. Respir. Crit. Care Med. 165, A271 (2002).
   Google Scholar
• Edelson J, Compton C, Nieman R et al. Cilomilast (Ariflo®) improves health status in patients with COPD: results of a 6 month trial. Am. J. Respir. Crit. Care Med. 163, A277 (2001).
   PubMedGoogle Scholar
• Knobil K, MA, Zhu J, Fischer T, Reisner C. Cilomilast is efficacious in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167, A97 (2003).
   Google Scholar
• Reisner C, Zhu J, Morris A, Lim J, Knobil K. Assessment of cardiac events via 24-hour electrocardiographic (Holter) monitoring with cilomilast in chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 167, A96 (2003).
   Google Scholar
• Zussman B, Kelly J, Rost K, Clark DJ, Ritchie SY, Bullman SMA. The effect of renal impairment on the disposition of cilomilast, a novel and selective oral PDE4 inhibitor. Am. J. Respir. Crit. Care Med. 165, A596 (2002).
   Google Scholar
• Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D. Cilomilast (Ariflo®) does not potentiate the cardiovascular effects of inhaled salbutamol. Pulm. Pharmacol. Ther. 15, 521–527 (2002).
   PubMedGoogle Scholar
• Zussman BD, Kelly J, Murdoch RD et al. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin. Ther. 23, 921–931 (2001).
   PubMedGoogle Scholar
• Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Ann. Pharmacother. 35, 1535–1539 (2001).
   PubMedGoogle Scholar
• Kelly J, Walls C, Murdoch RD et al. No interaction when erythromycin is co-administered with cilomilast at steady-state. Am. J. Respir. Crit. Care Med. 165, A596 (2002).
   Google Scholar
• Bagchi I, Bakst AW, Edelson JE, Amit O, Philadelphia P. Cilomilast reduces healthcare recource utilization of chronic obstructive pulmonary disease patients. Am. J. Respir. Crit. Care Med. 163, A507 (2001).
   Google Scholar
• Borker R, Spencer M, Knobil K, Zhu J, Jhingran P. Combining probabilistic uncertainty analysis with non-parametric bootstrap procedure to estimate the non-drug costs and effectiveness of cilomilast in COPD. Am. J. Respir. Crit. Care Med. 169, A328 (2004).
   PubMedGoogle Scholar
• Larson JL, Pino MV, Geiger LE, Simeone CR. The toxicity of repeated exposures to rolipram, a Type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78, 44–49 (1996).
   PubMedGoogle Scholar
• Robertson DG, Reily MD, Albassam M, Dethloff LA. Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol. 1, 7–19 (2001).
   PubMedGoogle Scholar
• Kelsen SG, Yang Y, Bin W, Li X, Aksoy MO. Cilomilast and salmeterol inhibit chemokine release by human airway epithelial cells. Am. J. Respir. Crit. Care Med. 165, A194 (2002).
   Google Scholar
• Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm. Pharmacol. Ther. 18, 9–17 (2005).
   PubMed Web of Science ®Google Scholar
• Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 347–360 (2003).
   PubMed Web of Science ®Google Scholar
• Ochiai H, Ohtani T, Ishida A et al. Orally-active PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem. Lett. 14, 1323–1327 (2004).
   PubMedGoogle Scholar
• Stebbins K, Provins L, Ellis J. Aerosol activity of phosphodiesterase Type IV inhibitors in amurine model of cigarette smoke induced pulmonary inflammation. Am. J. Respir. Crit. Care Med. 167, A486 (2003).
   PubMedGoogle Scholar
• Barnette MS, Christensen SB, Essayan DM et al. SB-207499 (Ariflo®), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284, 420–426 (1998).
   PubMed Web of Science ®Google Scholar
• Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. Effect of selective phosphodiesterase Type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 17, 333–344 (1993).
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm. Pharmacol. Ther. 18, 93–101 (2005).
   PubMed Web of Science ®Google Scholar
• Morcillo E, Cortijo J, Mtnez-Losa M, Seda E, Morazzoni G, Marchini F. Effects of selective phosphodiesterase 4 inhibitors on functional responses of human neutrophils and eosinophils. Am. J. Respir. Crit. Care Med. 163, A993 (2001).
   Google Scholar
• Baumer W, Gorr G, Hoppmann J, Ehinger AM, Ehinger B, Kietzmann M. Effects of the phosphodiesterase 4 inhibitors SB-207499 and AWD 1 2–281 on the inflammatory reaction in a model of allergic dermatitis. Eur. J. Pharmacol. 446, 195–200 (2002).
   PubMed Web of Science ®Google Scholar
• Au BT, Teixeira MM, Collins PD, Williams TJ. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br. J. Pharmacol. 123, 1260–1266 (1998).
   PubMedGoogle Scholar
• Cooper KD, Kang K, Chan SC, Hanifin JM. Phosphodiesterase inhibition by Ro 2 0–1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J. Invest. Dermatol. 84, 477–482 (1985).
   PubMed Web of Science ®Google Scholar
• Coqueret O, Boichot E, Lagente V. Selective Type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells. Clin. Exp. Allergy 27, 816–823 (1997).
   PubMedGoogle Scholar
• Thompson WJ, Ashikaga T, Kelly JJ et al. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem. Pharmacol. 63, 797–807 (2002).
   PubMedGoogle Scholar
• Baumer W, Tschernig T, Sulzle B, Seegers U, Luhrmann A, Kietzmann M. Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin. Eur. J. Pharmacol. 481, 271–279 (2003).
   PubMedGoogle Scholar
• Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int. Immunol. 15, 827–835 (2003).
   PubMedGoogle Scholar